Demirci Senem, Kamer Serra, Kara Gulsen, Yildirim Ozgur, Esassolak Mustafa
Department of Radiation Oncology, Ege University Faculty of Medicine, Bornova, Izmir, Turkey.
Acta Otolaryngol. 2011 Aug;131(8):852-60. doi: 10.3109/00016489.2011.560188. Epub 2011 Apr 8.
The survival rates and prognostic factors for nasopharyngeal cancer (NPC) were found to be similar to the published series from endemic regions.
The purpose of this retrospective study was to evaluate treatment outcome and prognostic factors of NPC patients treated with radiotherapy or chemoradiotherapy in a non-endemic region.
We analyzed clinical characteristics, treatment outcome, and prognostic factors of NPC patients in a non-endemic region, and compared our institution's results with the published literature including a similar patient population from endemic and non-endemic regions. Among 248 NPC patients, 71 (28.6%) were female and 177 (71.4%) were male with a median age of 48 years.
Within a median 59 months (range 22-178) of follow-up, local recurrence developed in 22 (8.9%), regional recurrence in 2 (0.8%), locoregional recurrence in 5 (2%), distant metastases in 21 (8.5%), and both locoregional recurrence and distant metastases in 8 (3.2%) patients. Five-year locoregional control (LRC), disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS) rates were 83.7%, 73%, 78.5%, and 71.1%, respectively. In multivariate analysis for LRC, cranial nerve involvement (CNI) (p = 0.009) and tumor response (p = 0.004); for DFS, age (p = 0.003), CNI (p = 0.02), AJCC T classification (p = 0.05), and tumor response (p = 0.01); for DSS, age (p = 0.003), CNI (p = 0.04), AJCC T classification (p = 0.04), and tumor response (p = 0.01); for OS, age (p < 0.001), AJCC T classification (p = 0.005), and tumor response (p < 0.001) were significant prognostic factors.
鼻咽癌(NPC)的生存率和预后因素与流行地区已发表的系列研究结果相似。
本回顾性研究的目的是评估在非流行地区接受放疗或放化疗的NPC患者的治疗效果和预后因素。
我们分析了非流行地区NPC患者的临床特征、治疗效果和预后因素,并将我们机构的结果与已发表的文献进行比较,这些文献包括来自流行和非流行地区的类似患者群体。在248例NPC患者中,女性71例(28.6%),男性177例(71.4%),中位年龄48岁。
在中位随访59个月(范围22 - 178个月)内,22例(8.9%)出现局部复发,2例(0.8%)出现区域复发,5例(2%)出现局部区域复发,21例(8.5%)出现远处转移,8例(3.2%)患者同时出现局部区域复发和远处转移。五年局部区域控制(LRC)、无病生存率(DFS)、疾病特异性生存率(DSS)和总生存率(OS)分别为83.7%、73%、78.5%和71.1%。在LRC的多因素分析中,颅神经受累(CNI)(p = 0.009)和肿瘤反应(p = 0.004);在DFS中,年龄(p = 0.003)、CNI(p = 0.02)、美国癌症联合委员会(AJCC)T分类(p = 0.05)和肿瘤反应(p = 0.01);在DSS中,年龄(p = 0.003)、CNI(p = 0.04)、AJCC T分类(p = 0.04)和肿瘤反应(p = 0.01);在OS中,年龄(p < 0.001)、AJCC T分类(p = 0.005)和肿瘤反应(p < 0.001)是显著的预后因素。